Ironwood Pharmaceuticals
IRWD
163 hedge funds and large institutions have $2.14B invested in Ironwood Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 67 increasing their positions, 42 reducing their positions, and 17 closing their positions.
127.53% more ownership
Funds ownership: 0% → 127.53% (+128%)
60% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 42
53% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 17
36% more call options, than puts
Call options by funds: $4M | Put options by funds: $2.94M
5% more funds holding
Funds holding: 155 → 163 (+8)
2% less capital invested
Capital invested by funds: $2.19B → $2.14B (-$48.3M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$86.2M |
| 2 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$15.4M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$11.3M |
| 4 |
CC
Carlson Capital
Dallas,
Texas
|
+$10.9M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$52.3M |
| 2 |
O
OrbiMed
New York
|
-$40.8M |
| 3 |
BM
Bridger Management
New York
|
-$30.8M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$16.2M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$11.5M |
IRWD Hedge Fund Activity: Q4 2016 in Review
163 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q4 2016, worth a combined $2.14B — down 2.2% from $2.19B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new IRWD positions and 17 closed out — a net gain of 9 holders — while 67 added to existing stakes and 42 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $86.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $52.3M sold.
- 163 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q4 2016, up from 155 in Q3 2016.
- Funds reported $2.14B of Ironwood Pharmaceuticals stock for Q4 2016, down 2.2% quarter-over-quarter.
- 26 funds opened new Ironwood Pharmaceuticals positions in Q4 2016 and 17 closed out, a net change of +9 holders.
- The largest Ironwood Pharmaceuticals buyer in Q4 2016 was T. Rowe Price Associates, an estimated $86.2M added.
- The largest Ironwood Pharmaceuticals seller in Q4 2016 was Consonance Capital Management, an estimated $52.3M sold.
Based on aggregated 13F filings for Q4 2016.